PPTA Twitter

PlasmaProteins Your #plasmadonation can make a difference in the lives of those living with rare conditions such as #hemophilia or alpha-1 antitrypsin deficiency, both of which can be treated with #plasmaprotein therapies. Learn more about why your donation matters: bit.ly/2kx5I0P

2 days ago.

PlasmaProteins Save the Date! International Plasma Awareness Week (IPAW) is just one month away. From Oct 7-11, help us recognize plasma donors and raise awareness about the life-saving value of #plasmaprotein therapies. Learn more: bit.ly/2KuL6QT #IPAW2019 pic.twitter.com/Rg2zgY0d19

4 days ago.

Donor ethics letter submitted to the Expert Panel on Immune Globulin Product Supply and Related Impacts in Canada

Ethicists and Economists express concerns about banning compensation for plasma donors with regards to ensuring the security of a safe Immune Globulin Product Supply.

PPTA News

PPTA Welcomes New Executive Director of European Division +

The Plasma Protein Therapeutics Association (PPTA) announced today that Maarten Van Baelen has joined the association as Executive Director, PPTA Europe. Maarten brings to PPTA more than 10 years in the life sciences arena, including as an advocate for access to generic, biosimilar and value-added medicines. He has represented the pharmaceutical sector’s interest in public forums, strategic policy development, and advocacy on key issues with the European Commission, National Competent Authorities, and other stakeholders.
Read More
Registration is now open for the Business Forum! +

Join us on October 17 in San Diego for the 2019 Business Forum! [PPTA Members only]

Click here to register for the 2019 Business Forum. Online registration will close October 10.
Read More
PPTA Statement on Immunoglobulin Access +

Recent media reports have described access issues regarding immunoglobulin (Ig) therapies relied on by people living with primary immunodeficiencies. The Plasma Protein Therapeutics Association (PPTA) is aware of these reports and is working with advocate groups, regulators, and member companies to identify solutions and ensure people can continue treating these serious conditions.
Read More